Vascular Solutions (VASC) Tops Q3 EPS by 2c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Vascular Solutions (VASC) '3-for-3' in 2015; Canaccord Genuity Reiterates Buy
October 21, 2015 11:07 AM EDTCanaccord Genuity reiterated a Buy rating and $41.50 price target on Vascular Solutions (NASDAQ: VASC), following the company's 3Q15 earnings results. VASC reported its 3rd straight quarter beat and raise in 2015, beating consensus' EPS by $0.02.
Analyst Jason Mills commented, "In terms of a beat and raise batting average,... More



